Download video

Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL

82 views

OncLive

5 years ago

Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL

Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL

Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL
0:51
Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL
by OncLive
AMPLIFY Trial: Acalabrutinib Plus Venetoclax for CLL
10:23
AMPLIFY Trial: Acalabrutinib Plus Venetoclax for CLL
by CLL Society
Dr. Barrientos Discusses Acalabrutinib in CLL
2:00
Dr. Barrientos Discusses Acalabrutinib in CLL
by OncLive
Dr. Woyach on 3-Year Follow-Up of Acalabrutinib\/Obinutuzumab Combo in CLL
1:20
Dr. Woyach on 3-Year Follow-Up of Acalabrutinib\/Obinutuzumab Combo in CLL
by OncLive
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-l...
2:57
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-l...
by ecancer
Dr. Logan Discusses Acalabrutinib in CLL
1:41
Dr. Logan Discusses Acalabrutinib in CLL
by OncLive
New Hope for MRD Recurrence? Daratumumab Proof-of-Concept Study | Krzysztof Jamroziak, MD | #EHA2025
2:46
New Hope for MRD Recurrence? Daratumumab Proof-of-Concept Study | Krzysztof Jamroziak, MD | #EHA2025
by HealthTree University for Multiple Myeloma
[CẢNH BÁO] Những Cặp Vitamin Tuyệt Đối Không Được Dùng Chung!
18:58
[CẢNH BÁO] Những Cặp Vitamin Tuyệt Đối Không Được Dùng Chung!
by Dr.D
Acalabrutinib, venetoclax and obinutuzumab upfront for CLL
1:59
Acalabrutinib, venetoclax and obinutuzumab upfront for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dr. Brown Discusses Acalabrutinib in CLL
1:21
Dr. Brown Discusses Acalabrutinib in CLL
by OncLive
Dr. Leslie on Real-World Outcomes of Patients With CLL Treated With Acalabrutinib
1:40
Dr. Leslie on Real-World Outcomes of Patients With CLL Treated With Acalabrutinib
by OncLive
Acalabrutinib and Obinutuzumab for Frontline CLL Treatment
8:31
Acalabrutinib and Obinutuzumab for Frontline CLL Treatment
by CLL Society
Nanoparticle vaccine prevents multiple cancers and stops metastasis in mice
2:41
Nanoparticle vaccine prevents multiple cancers and stops metastasis in mice
by Hidoc Drug Info
Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLL
1:15
Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLL
by OncLive
Acalabrutinib-obinutuzumab in CLL: 3-year follow-up
1:11
Acalabrutinib-obinutuzumab in CLL: 3-year follow-up
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dr. Awan on Utilizing Acalabrutinib in CLL
1:22
Dr. Awan on Utilizing Acalabrutinib in CLL
by OncLive
Dr. Gerson on Venetoclax\/Obinutuzumab Combination in CLL
1:02
Dr. Gerson on Venetoclax\/Obinutuzumab Combination in CLL
by OncLive
Continued Benefit of Acalabrutinib with or without Obinutuzumab in CLL - ASH 2023
8:10
Continued Benefit of Acalabrutinib with or without Obinutuzumab in CLL - ASH 2023
by CLL Society
ASH 2017: Acalabrutinib Therapy for R\/R Mantle Cell Lymphoma
4:41
ASH 2017: Acalabrutinib Therapy for R\/R Mantle Cell Lymphoma
by NE Live
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline CLL
3:18
Benjamin Lampson: Acalabrutinib Combo Leads to Deep, Durable Responses in Frontline CLL
by American Society of Hematology
Combined acalabrutinib treatments for CLL
1:22
Combined acalabrutinib treatments for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Acalabrutinib Appears Tolerable in Chronic Lymphocytic Leukemia
0:57
Acalabrutinib Appears Tolerable in Chronic Lymphocytic Leukemia
by Targeted Oncology